May 08, 2012 / 7:30 am, CEST
Lanthio Pharma B.V., the Dutch peptide drug discovery company, announced today that a Project proposal in collaboration with the University of Groningen has been awarded a grant of €121,000 from SNN and €55,000 from the Province of Groningen. The Project concerns a 2 year collaboration of Lanthio Pharma with the Molecular Genetics Department, University of Groningen.
Expanding the toolbox of Lanthio Pharma to generate peptides with high therapeutic potential.
Goal of the Project is to develop the technology to enzymatically introduce larger intramolecular bridges in peptide therapeutics. This will expand the possibilities to generate therapeutics with highly specific receptor interaction and good drug-like properties due to resistance to breakdown by peptidases. In particular the technology will enable to stabilize alpha helix structures, which are important for receptor interactions. The Molecular Genetics Department headed by Prof. Dr. O.P. Kuipers has large experience with posttranslational modifications of peptides in Gram-positive micro-organisms which for this Project constitutes a perfect complementarity with Lanthio Pharma’s know how.